[Paper-level Aggregated] PMCID: PMC5355930

Evidence Type(s): Oncogenic

Summary: Mutation: H1047R | Summary: The H1047R mutation is identified as a prevalent PIK3CA HS mutation in patients, indicating its contribution to tumor development or progression.

Evidence Type: Oncogenic Mutation: E545K | Summary: The E545K mutation is noted as one of the prevalent PIK3CA HS mutations, suggesting its role in tumor development or progression.

Evidence Type: Oncogenic Mutation: E542K | Summary: The E542K mutation is mentioned as a prevalent PIK3CA HS mutation, indicating its involvement in tumor development or progression.

Gene→Variant (gene-first): PIK3CA(5290):H1047R PIK3CA(5290):E545K PIK3CA(5290):E542K

Genes: PIK3CA(5290)

Variants: H1047R E545K E542K

[Paper-level Aggregated] PMCID: PMC5355930

Evidence Type(s): Prognostic

Summary: Mutation: E542K | Summary: The E542K mutation is associated with shorter progression-free survival (PFS) and overall survival compared to wild-type PIK3CA, indicating a potential prognostic role in disease outcome.

Evidence Type: Prognostic Mutation: E545K | Summary: The E545K mutation is associated with shorter progression-free survival (PFS) and overall survival compared to wild-type PIK3CA, indicating a potential prognostic role in disease outcome.

Gene→Variant (gene-first): PIK3CA(5290):E542K PIK3CA(5290):E545K

Genes: PIK3CA(5290)

Variants: E542K E545K

[Paper-level Aggregated] PMCID: PMC5355930

Evidence Type(s): Diagnostic

Summary: Mutation: H1047R | Summary: The H1047R mutation is used to define patient subgroups based on PIK3CA mutations in the context of treatment analysis.

Evidence Type: Diagnostic Mutation: E545K | Summary: The E545K mutation is used to define patient subgroups based on PIK3CA mutations in the context of treatment analysis.

Evidence Type: Diagnostic Mutation: E542K | Summary: The E542K mutation is used to define patient subgroups based on PIK3CA mutations in the context of treatment analysis.

Gene→Variant (gene-first): PIK3CA(5290):H1047R PIK3CA(5290):E545K PIK3CA(5290):E542K

Genes: PIK3CA(5290)

Variants: H1047R E545K E542K

[Paper-level Aggregated] PMCID: PMC5355930

Evidence Type(s): Predictive

Summary: Mutation: H1047R | Summary: The H1047R mutation in PIK3CA correlates with prolonged median progression-free survival (PFS) and response to everolimus, indicating its predictive value for treatment sensitivity.

Evidence Type: Predictive Mutation: E545K | Summary: The E545K mutation in PIK3CA is associated with prolonged median progression-free survival (PFS) and response to everolimus, suggesting a predictive response to this therapy and indicating a potential predictive value regarding treatment sensitivity.

Evidence Type: Predictive Mutation: E542K | Summary: The E542K mutation in PIK3CA correlates with prolonged median progression-free survival (PFS) and response to everolimus, indicating its predictive value for treatment sensitivity and suggesting a role in resistance to hormone therapy.

Gene→Variant (gene-first): PIK3CA(5290):H1047R PIK3CA(5290):E545K PIK3CA(5290):E542K

Genes: PIK3CA(5290)

Variants: H1047R E545K E542K

[Paragraph-level] PMCID: PMC5355930 Section: ABSTRACT PassageIndex: 6

Evidence Type(s): Predictive

Summary: Evidence Type: Predictive | Mutation: H1047R | Summary: The H1047R mutation correlates with response to everolimus, indicating its predictive value for treatment sensitivity. Evidence Type: Predictive | Mutation: E545K | Summary: The E545K mutation correlates with response to everolimus, indicating its predictive value for treatment sensitivity. Evidence Type: Predictive | Mutation: E542K | Summary: The E542K mutation correlates with response to everolimus, indicating its predictive value for treatment sensitivity.

Gene→Variant (gene-first): 5290:E542K 5290:E545K 5290:H1047R

Genes: 5290

Variants: E542K E545K H1047R

[Paragraph-level] PMCID: PMC5355930 Section: ABSTRACT PassageIndex: 4

Evidence Type(s): Diagnostic

Summary: Evidence Type: Diagnostic | Mutation: H1047R | Summary: The H1047R mutation is used to define patient subgroups based on PIK3CA mutations in the context of treatment analysis. Evidence Type: Diagnostic | Mutation: E545K | Summary: The E545K mutation is used to define patient subgroups based on PIK3CA mutations in the context of treatment analysis. Evidence Type: Diagnostic | Mutation: E542K | Summary: The E542K mutation is used to define patient subgroups based on PIK3CA mutations in the context of treatment analysis.

Gene→Variant (gene-first): 5290:E542K 5290:E545K 5290:H1047R

Genes: 5290

Variants: E542K E545K H1047R

[Paragraph-level] PMCID: PMC5355930 Section: RESULTS PassageIndex: 9

Evidence Type(s): Prognostic, Predictive

Summary: Evidence Type: Prognostic | Mutation: E542K | Summary: The E542K mutation is associated with shorter progression-free survival (PFS) and overall survival compared to wild-type PIK3CA, indicating a potential prognostic role in disease outcome. Evidence Type: Prognostic | Mutation: E545K | Summary: The E545K mutation is associated with shorter progression-free survival (PFS) and overall survival compared to wild-type PIK3CA, indicating a potential prognostic role in disease outcome. Evidence Type: Predictive | Mutation: E542K | Summary: The E542K mutation suggests a role in resistance to hormone therapy, indicating a potential predictive value regarding treatment response. Evidence Type: Predictive | Mutation: E545K | Summary: The E545K mutation suggests a role in resistance to hormone therapy, indicating a potential predictive value regarding treatment response.

Gene→Variant (gene-first): 5290:E542K 5290:E545K

Genes: 5290

Variants: E542K E545K

[Paragraph-level] PMCID: PMC5355930 Section: RESULTS PassageIndex: 8

Evidence Type(s): Predictive

Summary: Evidence Type: Predictive | Mutation: H1047R | Summary: The H1047R mutation in PIK3CA correlates with prolonged median progression-free survival (PFS) in patients treated with everolimus, indicating a predictive response to this therapy. Evidence Type: Predictive | Mutation: E545K | Summary: The E545K mutation in PIK3CA is associated with prolonged median progression-free survival (PFS) in patients treated with everolimus, suggesting a predictive response to this therapy. Evidence Type: Predictive | Mutation: E542K | Summary: The E542K mutation in PIK3CA correlates with prolonged median progression-free survival (PFS) in patients treated with everolimus, indicating a predictive response to this therapy.

Gene→Variant (gene-first): 5290:E542K 5290:E545K 5290:H1047R

Genes: 5290

Variants: E542K E545K H1047R

[Paragraph-level] PMCID: PMC5355930 Section: RESULTS PassageIndex: 3

Evidence Type(s): Oncogenic

Summary: Evidence Type: Oncogenic | Mutation: H1047R | Summary: The H1047R mutation is identified as a prevalent PIK3CA HS mutation in patients, indicating its contribution to tumor development or progression. Evidence Type: Oncogenic | Mutation: E545K | Summary: The E545K mutation is noted as one of the prevalent PIK3CA HS mutations, suggesting its role in tumor development or progression. Evidence Type: Oncogenic | Mutation: E542K | Summary: The E542K mutation is mentioned as a prevalent PIK3CA HS mutation, indicating its involvement in tumor development or progression.

Gene→Variant (gene-first): 5290:E542K 5290:E545K 5290:H1047R

Genes: 5290

Variants: E542K E545K H1047R

[Paper-level Aggregated] PMCID: PMC5355930

Evidence Type(s): Predictive, Prognostic, Oncogenic

Justification: Predictive: The text indicates that the presence of PIK3CA mutations, specifically H1047R, E545K, and E542K, is associated with different progression-free survival (PFS) outcomes in patients treated with everolimus, suggesting these mutations can predict treatment efficacy. Prognostic: The analysis shows that patients with E545K/E542K mutations had shorter PFS and overall survival compared to those with wild-type PIK3CA in the placebo arm, indicating these mutations may have prognostic implications regarding disease outcome. Oncogenic: The presence of PIK3CA mutations, including E542K, E545K, and H1047R, is associated with tumor behavior and treatment response, suggesting these mutations contribute to oncogenesis in the context of cancer.

Gene→Variant (gene-first): PIK3CA(5290):E542K PIK3CA(5290):E545K PIK3CA(5290):H1047R

Genes: PIK3CA(5290)

Variants: E542K E545K H1047R

[Paragraph-level] PMCID: PMC5355930 Section: ABSTRACT PassageIndex: 6

Evidence Type(s): Predictive, Oncogenic

Justification: Predictive: The passage discusses the correlation between PIK3CA mutations (H1047R, E545K, E542K) and the response to the therapy everolimus, indicating that these variants are associated with treatment outcomes. Oncogenic: The mention of PIK3CA mutations in the context of tumor analysis suggests that these somatic variants contribute to tumor development or progression, particularly in relation to their response to therapy.

Gene→Variant (gene-first): 5290:E542K 5290:E545K 5290:H1047R

Genes: 5290

Variants: E542K E545K H1047R

[Paragraph-level] PMCID: PMC5355930 Section: ABSTRACT PassageIndex: 4

Evidence Type(s): Diagnostic, Prognostic

Justification: Diagnostic: The passage discusses the analysis of PIK3CA mutations to define patient subgroups, indicating that these variants are used to classify or associate with a disease or subtype. Prognostic: The mention of estimating median progression-free survival (PFS) for patient subgroups defined by PIK3CA mutations suggests a correlation with disease outcome independent of therapy.

Gene→Variant (gene-first): 5290:E542K 5290:E545K 5290:H1047R

Genes: 5290

Variants: E542K E545K H1047R

[Paragraph-level] PMCID: PMC5355930 Section: RESULTS PassageIndex: 9

Evidence Type(s): Predictive, Prognostic

Justification: Predictive: The passage suggests that patients with E545K/E542K mutations had shorter progression-free survival (PFS) and overall survival, indicating a potential role of these mutations in resistance to hormone therapy. Prognostic: The mention of shorter PFS and overall survival in patients with the E545K/E542K mutations indicates a correlation with disease outcome independent of therapy.

Gene→Variant (gene-first): 5290:E542K 5290:E545K

Genes: 5290

Variants: E542K E545K

[Paragraph-level] PMCID: PMC5355930 Section: RESULTS PassageIndex: 8

Evidence Type(s): Predictive, Oncogenic

Justification: Predictive: The passage discusses the correlation between PIK3CA mutations (H1047R, E545K, E542K) and the efficacy of everolimus, indicating that these variants are associated with prolonged progression-free survival (PFS) in patients treated with this therapy. Oncogenic: The mention of PIK3CA mutations in the context of their role in tumor development and the efficacy of a cancer treatment suggests that these somatic variants contribute to tumor progression.

Gene→Variant (gene-first): 5290:E542K 5290:E545K 5290:H1047R

Genes: 5290

Variants: E542K E545K H1047R

[Paragraph-level] PMCID: PMC5355930 Section: RESULTS PassageIndex: 3

Evidence Type(s): Diagnostic, Predictive

Justification: Diagnostic: The passage discusses the prevalence of PIK3CA mutations, including specific variants, in a patient population, indicating their association with the disease context. Predictive: The mention of higher prevalence of PIK3CA mutations in the everolimus arm compared to the placebo arm suggests a correlation with treatment response, indicating predictive value.

Gene→Variant (gene-first): 5290:E542K 5290:E545K 5290:H1047R

Genes: 5290

Variants: E542K E545K H1047R

[Paragraph-level] PMCID: PMC5355930 Section: ABSTRACT PassageIndex: 6

Evidence Type(s): Predictive, Oncogenic

Justification: Predictive: The passage discusses the correlation between PIK3CA mutations (H1047R, E545K, E542K) and the response to the therapy everolimus, indicating that these variants are associated with treatment outcomes. Oncogenic: The mention of PIK3CA mutations in the context of tumor analysis suggests that these somatic variants contribute to tumor development or progression, particularly in relation to their response to therapy.

Gene→Variant (gene-first): 5290:E542K 5290:E545K 5290:H1047R

Genes: 5290

Variants: E542K E545K H1047R

[Paragraph-level] PMCID: PMC5355930 Section: ABSTRACT PassageIndex: 4

Evidence Type(s): Diagnostic, Prognostic

Justification: Diagnostic: The passage discusses the analysis of PIK3CA mutations to define patient subgroups, indicating that these variants are used to classify or associate with a disease or subtype. Prognostic: The mention of estimating median progression-free survival (PFS) for patient subgroups defined by PIK3CA mutations suggests a correlation with disease outcome independent of therapy.

Gene→Variant (gene-first): 5290:E542K 5290:E545K 5290:H1047R

Genes: 5290

Variants: E542K E545K H1047R

[Paragraph-level] PMCID: PMC5355930 Section: RESULTS PassageIndex: 9

Evidence Type(s): Predictive, Prognostic

Justification: Predictive: The passage suggests that patients with E545K/E542K mutations had shorter progression-free survival (PFS) and overall survival, indicating a potential role of these mutations in resistance to hormone therapy. Prognostic: The mention of shorter PFS and overall survival in patients with the E545K/E542K mutations indicates a correlation with disease outcome independent of therapy.

Gene→Variant (gene-first): 5290:E542K 5290:E545K

Genes: 5290

Variants: E542K E545K

[Paragraph-level] PMCID: PMC5355930 Section: RESULTS PassageIndex: 8

Evidence Type(s): Predictive, Oncogenic

Justification: Predictive: The passage discusses the correlation between PIK3CA mutations (H1047R, E545K, E542K) and the efficacy of everolimus, indicating that these variants are associated with prolonged progression-free survival (PFS) in patients treated with this therapy. Oncogenic: The mention of PIK3CA mutations in the context of their role in tumor development and the efficacy of a cancer treatment suggests that these somatic variants contribute to tumor progression.

Gene→Variant (gene-first): 5290:E542K 5290:E545K 5290:H1047R

Genes: 5290

Variants: E542K E545K H1047R

[Paragraph-level] PMCID: PMC5355930 Section: RESULTS PassageIndex: 3

Evidence Type(s): Diagnostic, Predictive

Justification: Diagnostic: The passage discusses the prevalence of PIK3CA mutations, including specific variants, in a patient population, indicating their association with the disease context. Predictive: The mention of higher prevalence of PIK3CA mutations in the everolimus arm compared to the placebo arm suggests a correlation with treatment response, indicating predictive value.

Gene→Variant (gene-first): 5290:E542K 5290:E545K 5290:H1047R

Genes: 5290

Variants: E542K E545K H1047R